Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Turk J Pediatr ; 66(3): 323-331, 2024 07 11.
Artículo en Inglés | MEDLINE | ID: mdl-39024603

RESUMEN

BACKGROUND: Pulmonary Langerhans cell histiocytosis (pLCH) is a rare disease, mostly a component of multisystemic LCH. We aimed to investigate the clinical features and treatment results in children with pLCH. METHODS: We retrospectively reviewed the clinical, radiological, and treatment data of 37 patients with pLCH, diagnosed from 1974 to 2022. RESULTS: 10% (n=37) of 367 patients with LCH had lung involvement. The median age was 1.8 years (range: 0.4 & 17.7) with a male-to-female ratio of 2.3. At admission 29.7% (n=11) presented with respiratory symptoms. Imaging showed a spectrum from nodular opacities to multiple cysts. All but one patient had multisystem disease. Twenty-nine received vinblastine-containing therapy. Ten-year event-free (EFS) and overall survival (OS) rates were 47.8% and 63.3%, respectively. In children younger and older than two years of age, the 10-year EFS was 53.3% vs. 40.2% and the 10-year OS was 58.7% vs. 68.8%, respectively. In children with and without risk organ involvement, 10-year EFS was 51.9% vs. 46.3% and 10-year OS was 51.9% vs. 73.7%. CONCLUSIONS: Lung and multisystem involvement are significant concerns in LCH, highlighting the need for careful management to reduce morbidity and mortality.


Asunto(s)
Histiocitosis de Células de Langerhans , Enfermedades Pulmonares , Humanos , Histiocitosis de Células de Langerhans/complicaciones , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Histiocitosis de Células de Langerhans/diagnóstico , Masculino , Femenino , Estudios Retrospectivos , Preescolar , Lactante , Niño , Adolescente , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/diagnóstico , Tasa de Supervivencia/tendencias
2.
J Neurooncol ; 162(2): 443-448, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-37039951

RESUMEN

PURPOSE: To determine long-term outcomes of a cohort of children with germinoma treated with chemotherapy and radiation therapy without primary tumor boost even in the absence of complete response to chemotherapy METHODS: This retrospective study analyzed the outcome of patients with germinoma consecutively diagnosed and treated at a tertiary care center from January 2000 to December 2021. MRIs were reviewed by two radiologists, blinded to patient data. Tumor location at diagnosis, tumor response to chemotherapy and at completion of radiation therapy and site of relapse were assessed. Tumor response was assessed radiologically by determining the tumor size and response on diffusion-weighted imaging, in addition to biochemical, cytological parameters and neurological status. RESULTS: Of 46 pediatric germinoma patients, 29 children (14 male; median age 12.8 years) received no primary tumor boost. Median follow-up was 63 months (range 9-187 months). Twenty-five children had localized disease and tumor location was suprasellar (n = 11), pineal (n = 10), bifocal (n = 3) and basal ganglia (n = 1) while 4 children had metastatic disease at presentation. All patients completed multi-agent chemotherapy followed by either ventricular irradiation (VI) (23.4 Gy) (n = 23), whole brain (WBI) (23.4 Gy) (n = 5) or craniospinal radiation (CSI) (23.4 Gy) (n = 1). Two children, who had localized disease at presentation and received VI after chemotherapy, relapsed 9 months and 32 months after completion of treatment respectively. No patient had a local relapse. Location of relapse was distant, outside (n = 1) and out- and inside (n = 1) the irradiation field. Five-year progression free survival (PFS) was 91% and overall survival (OS) was 100%. CONCLUSIONS: In this case series, excellent 5-year PFS and OS rates were achieved with chemotherapy followed by radiation therapy of 23.4 Gy delivered without primary tumor boost. No local relapse was observed despite omitting primary tumor boost in patients with localized and metastatic germinoma.


Asunto(s)
Neoplasias Encefálicas , Germinoma , Niño , Humanos , Masculino , Estudios Retrospectivos , Neoplasias Encefálicas/terapia , Neoplasias Encefálicas/tratamiento farmacológico , Recurrencia Local de Neoplasia/patología , Germinoma/terapia , Germinoma/tratamiento farmacológico , Encéfalo/patología , Dosificación Radioterapéutica , Estudios de Seguimiento
3.
J Pediatr Hematol Oncol ; 44(7): 402-404, 2022 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-35536996

RESUMEN

Ifosfamide is an important chemotherapeutic agent used in the therapeutic protocols of many malignant tumors. Central nervous system toxicity of ifosfamide manifests with encephalopathy in 10% to 30% of patients treated with ifosfamide. Thiamine and methylene blue have been reported beneficial in the treatment and prevention of ifosfamide-induced encephalopathy (IIE). We describe an episode of encephalopathy developed at the third cycle of ifosfamide treatment in a child with Ewing sarcoma. With the administration of thiamin, the encephalopathy resolved and no episode was noted during subsequent courses of ifosfamide. Previous use of cisplatin, concomitant use of opioids, low levels of serum albumin and hemoglobin, and elevated levels of serum creatinine are potential risk factors for IIE. The current case illustrates the possibility of IIE even in the absence of such additional risk factors, treated successfully with thiamin and draws attention to the need for close neurological monitorization of patients treated with ifosfamide.


Asunto(s)
Encefalopatías , Ifosfamida , Antineoplásicos Alquilantes/efectos adversos , Encefalopatías/inducido químicamente , Encefalopatías/tratamiento farmacológico , Niño , Cisplatino/efectos adversos , Creatinina , Humanos , Ifosfamida/efectos adversos , Azul de Metileno/uso terapéutico , Albúmina Sérica , Tiamina/uso terapéutico
5.
Turk J Pediatr ; 61(3): 325-329, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31916708

RESUMEN

Yaman-Bajin I, Aytaç S, Kuskonmaz B, Uçkan-Çetinkaya D, Ünal S, Gümrük F, Çetin M. Infant lymphoblastic leukemia: a single centers 10 year experience. Turk J Pediatr 2019; 61: 325-329. Infant acute lymphoblastic leukemia (ALL) is a rare disease and consists of 4-5% of all childhood ALL. Despite improved survival rates in childhood ALL, infants with ALL have a worse prognosis. We aimed to evaluate the clinical features and treatment outcomes of our patients diagnosed with infant ALL at Hacettepe University, Pediatric Hematology Department between 1 January 2008 and 1 January 2018 retrospectively. There were 13 patients with a median age of 7 months. Three of the patients were triplets born from a spontaneous monozygotic triplet pregnancy. Relapse were observed in 4 patients. Hematopoietic stem cell transplantation (HSCT) was performed for five patients. Relapse after HSCT was observed in 3 patients. After a median follow-up period of 18 months, 6 patients (45%) (3 after HSCT and 3 who only received chemotherapy) were alive and in remission. Prognosis of infant ALL is poor in that only half of the patients survive. Our results suggest that bone marrow transplantation seems to be a good and efficient choice of treatment for selected patients. However, there is still a big issue to decide which patient should undergo transplantation and more studies are needed to reevaluate the eligibility criteria for HSCT in this group of patients.


Asunto(s)
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Femenino , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Hospitales Universitarios , Humanos , Lactante , Recién Nacido , Masculino , Recurrencia , Inducción de Remisión , Estudios Retrospectivos , Trillizos , Turquía/epidemiología
6.
Turk J Pediatr ; 61(3): 456-459, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31916730

RESUMEN

Özyörük D, Kocayozgat A, Yaman-Bajin I, Çetindag F, Oguz- Erdogan AS, Günes A. A synchronous occurrence of bifocal intracranial germinoma and bilateral testicular epidermoid cyst in an adolescent patient with Klinefelter`s syndrome. Turk J Pediatr 2019; 61: 456-459. Klinefelter syndrome (KS) is characterized by an additional X chromosome in males leading to a karyotype of 47,XXY. It is associated with an increased risk of certain malignancies, including leukemia, breast cancer and extragonadal germ cell tumor such as mediastinal germ cell tumors and rarely intracranial germ cell tumors. It is possible that the increased risk of developing certain cancers can be attributed to a direct effect of the chromosomal abnormality or the combined action of the abnormal chromosomes and hormonal imbalances. Here we describe a synchronous occurrence of bifocal intracranial germinoma and bilateral testicular epidermoid cyst in an adolescent patient with Klinefelter`s syndrome. The synchronous occurrence of the dual tumors in this patient with Klinefelter`s syndrome might be resulted from the migration defect during embriyogenesis due to underlying genetic disease or it is a coincidental condition, yet there has been no case reported in the literature, so far.


Asunto(s)
Neoplasias Encefálicas/complicaciones , Quiste Epidérmico/complicaciones , Germinoma/complicaciones , Síndrome de Klinefelter/complicaciones , Enfermedades Testiculares/complicaciones , Adolescente , Biopsia , Encéfalo/diagnóstico por imagen , Neoplasias Encefálicas/diagnóstico , Diagnóstico Diferencial , Quiste Epidérmico/diagnóstico , Germinoma/diagnóstico , Humanos , Síndrome de Klinefelter/diagnóstico , Imagen por Resonancia Magnética , Masculino , Enfermedades Testiculares/diagnóstico
7.
J Pediatr Hematol Oncol ; 41(3): e197-e200, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30299348

RESUMEN

Burkitt lymphoma manifesting as an intracardiac mass is a rare entity. This report describes the case of a 10-year-old boy who presented with an intracardiac mass and tumor thrombosis in the anterior mediastinum that proved to be Burkitt lymphoma. The LMB-96 chemotherapy protocol was given and at the end of the treatment there was still residual mass. A biopsy was performed and the pathology revealed thymus tissue. The patient has been in complete remission for 3 months. Burkitt lymphoma has a short doubling time and an intracardiac lesion can become life threatening. Early recognition and prompt treatment are crucial in achieving optimal outcomes.


Asunto(s)
Linfoma de Burkitt/diagnóstico , Neoplasias Cardíacas/patología , Mediastino/patología , Trombosis/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biopsia , Niño , Neoplasias Cardíacas/diagnóstico , Humanos , Masculino , Neoplasias/complicaciones , Inducción de Remisión , Timo/patología
8.
J Pediatr Hematol Oncol ; 40(1): 48-50, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28787395

RESUMEN

Osteosarcoma is the most common primary malignant tumor of the bone. The most common sites of osteosarcoma in children are the metaphysis of long bones, especially the distal femur, proximal tibia, and proximal humerus. It occurs very rarely in flat bones. Here we report a 14-year-old adolescent boy with primary osteosarcoma of the fifth rib and a review of literature.


Asunto(s)
Neoplasias Óseas/diagnóstico , Osteosarcoma/diagnóstico , Costillas/patología , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Resultado Fatal , Humanos , Masculino , Osteosarcoma/tratamiento farmacológico , Insuficiencia del Tratamiento
9.
Pediatr Surg Int ; 31(7): 677-81, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25994562

RESUMEN

Secretory breast carcinoma (SBC) is a rare type of breast neoplasia that was originally described in children. SBC is an indolent breast tumor with good clinical outcome and rare systemic involvement. Since, majority of studies concerning pediatric SBC have been case reports, it has been difficult to clearly elucidate the characteristics and optimal treatment strategies for SBC in children. Although treatment recommendations vary, surgical excision is the primary mode of treatment. Also, necessity of axillary and/or sentinel lymph node dissection is another matter of discussion in children. We report a 6-year-old girl who was diagnosed as SBC was reported to discuss the use of mastectomy with sentinel lymph node dissection in the treatment of this rare tumor in children.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma/cirugía , Escisión del Ganglio Linfático , Ganglios Linfáticos/cirugía , Mastectomía , Niño , Femenino , Humanos , Biopsia del Ganglio Linfático Centinela
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...